SAN DIEGO, March 4, 2021 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that the company will participate in three
upcoming investor conferences.
Details of the company's participation are as follows:
- HC Wainwright Global Life Science Conference
Details:
Viking management will deliver a corporate presentation and
participate in 1-on-1 meetings
Conference dates: March 9-10,
2021
Presentation Timing: Available online at 7:00 a.m. Eastern on Tuesday, March 9, 2021
Format: Virtual conference; webcast available
- 33rd Annual Roth Conference
Details:
Viking management will participate in 1-on-1 meetings
Conference Date: March 15-17,
2021
Format: Virtual Conference
- Oppenheimer's 31st Annual Healthcare
Conference
Details: Viking management will deliver a
corporate presentation and participate in 1-on-1 meetings
Conference Date: March 16-18,
2021
Presentation Time/Date: 1:50 – 2:20
p.m. Eastern on Tuesday, March 16,
2021
Format: Virtual conference; webcast available
Webcasts of the H.C. Wainwright and Oppenheimer presentations
may be accessed via a link on the Viking Therapeutics website in
the Investors & Media section under Webcasts.
Additionally, replays of the webcasts will be available on the
Viking website following the conferences.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel, orally available,
first-in-class or best-in-class therapies for the treatment of
metabolic and endocrine disorders. Viking's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of lipid and metabolic
disorders, which is currently being evaluated in a
Phase 2b study for the treatment of biopsy-confirmed
non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase
2 trial for the treatment of non-alcoholic fatty liver disease
(NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company is also developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the potential treatment of X-linked
adrenoleukodystrophy (X-ALD). VK0214 is currently being
evaluated in a Phase 1 first-in-human clinical trial. The
company holds exclusive worldwide rights to a portfolio of five
therapeutic programs, including those noted above, which are based
on small molecules licensed from Ligand Pharmaceuticals
Incorporated.
For more information about Viking Therapeutics, please visit
www.vikingtherapeutics.com. Follow Viking on Twitter
@Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-301240245.html
SOURCE Viking Therapeutics, Inc.